• Skip to main content
  • Skip to navigation
  • Accessibility
  • Contact Us
Government of Western Australia Crest
Government of Western Australia
Government of Western Australia Crest

Additional Menu

  • Accessibility
  • Contact us
Go to WA Government search
  • About Us
    • Health Service Board
    • Executive
    • Our Vision and Values
      • Excellence Symposium
      • Values in Action Award
    • Strategic Planning
    • Work with Us
      • Vacancies
      • Careers at EMHS
      • Pay and Benefits
      • How to Join Us
      • Pathways to Working with Us
      • Equity, Diversity and Inclusion
      • Multicultural Advisory Group
      • Frequently Asked Questions
    • Annual Reports
    • Accessing Records
      • Accessing Records via Freedom of Information
      • Accessing Records via the Mental Health Act
    • Governance
    • Contact Us
      • Compliments or complaints
      • Reporting Misconduct
  • Hospitals and Services
    • Aboriginal Health
      • Moorditj Djena – Strong Feet
      • Aboriginal Health Strategy
    • Hospitals
      • Armadale Health Service
      • Bentley Health Service
      • Byford Health Hub
      • Kalamunda Hospital
      • Royal Perth Hospital
      • St John of God Midland Public Hospital
    • Health Promotion
      • Overview
      • Alcohol
      • Nutrition
      • Obesity
      • Physical Activity
      • Smoking
    • Mental Health, Alcohol and Other Drugs
      • Community Services
      • Inpatient and Other Services
    • Services
      • Aishwarya's CARE Call
      • Elective Surgery
      • EMHS Post COVID-19 Clinic
      • Home Hospital
      • Medihotels
      • Emergency Departments
      • Health Technology Management Unit
      • HIVE – Health in a Virtual Environment
      • Maternity Services
      • State Trauma Services
    • Parking at EMHS
    • Voluntary Assisted Dying
  • Patient Care
    • Safety and Quality
      • Preventing Complications in Hospital
      • Preventing Infections in Our Health Service
      • Caring for Our Mental Health Clients
      • Getting It Right the First Time
      • Learning for Patient Safety
      • Care Opinion
      • The Patient Experience
    • Partnering with Consumers
      • Consumer Advisory Committees
      • Volunteering
      • Wool-lar Aboriginal Volunteer Program
    • Choosing Wisely
    • Carers Charter
    • Patient Resources
    • Disability Access and Inclusion Plan
  • Health Professionals
    • Central Referral Service
    • Contracted Medical Practitioners
    • Library and Information Service
  • Innovation
  • Research
    • About Our Research
      • Anaesthesia & Pain Medicine
      • Cardiology
      • Cell & Tissue Therapies WA
      • Emergency Medicine
      • EMHS Bioengineering
      • Geriatric Medicine
      • Health in a Virtual Environment (HIVE)
      • RPH Cardiometabolic and Hypertension Service
      • RPH Gastroenterology and Hepatology
      • RPH Haematology
      • RPH Intensive Care Unit
      • RPH Microbiology and Infectious Diseases
      • RPH Nephrology - Renal
      • RPH Orthopaedic Surgery
      • RPH Respiratory Medicine
      • RPH Trauma Service
      • RPH Vascular Surgery
    • Research News
    • Research Strategy
    • For Researchers
      • Research Ethics and Governance Submissions
      • Ethics Information and Tips
      • Governance Information and Tips
      • Amendments and Safety Reports
      • Education, Training and Seminars
      • Grant Opportunities
      • Resources
    • Foundation and Network Partners
  • News
  1. Home
  2. News
  3. 2021
  4. 06
  5. 22
  6. RPH Anaesthetist leads milestone trial

RPH Anaesthetist leads milestone trial

RPH Anaesthetist leads milestone trial

Photograph of staff hanging out on the colourful rainbow bridge
28/05/2021

A large scale trial by Monash University has definitively found a drug commonly used during anaesthesia before surgery to prevent nausea and vomiting does not increase the risk of a surgical wound infection as once feared.

Professor Tomás Corcoran, Director of Research in the Department of Anaesthesia and Pain Medicine, at Royal Perth Hospital and Adjunct Clinical Professor in the Central Clinical School at Monash University, was the lead researcher in the Perioperative Administration of Dexamethasone and Infection Trial (PADDI) (external link).

Tomas said that the study had the potential to influence anaesthesia practice around the world.

“The steroid drug, dexamethasone, is often given by anaesthetists during surgery,” he said.

“However, because of its effects on the immune system there has been growing concern that it may increase the risk of wound infections, particularly in vulnerable populations such as patients with diabetes.

“As a result, there has been a reluctance to use it, even though more than half of patients are at risk of experiencing nausea and vomiting after their surgery.”

Interestingly, the same drug was recently been shown to decrease the risk of death from COVID-19 in severely ill patients.

Tomas said that the large clinical trial - led by Monash University and the Australian and New Zealand College of Anaesthetists Clinical Trials Network - found that administering a low-dose of dexamethasone during anaesthesia for surgical operations does not increase the risk of surgical wound infections.

It found the drug may be safely given to patients undergoing surgery without causing an increase in these infections, including to patients with diabetes.

“This is an important finding because these infections are common,” he said.

In Australia alone, there are at least 200,000 healthcare-associated infections including wound infections that are diagnosed in hospital patients each year, costing approximately $1 billion a year.

The Paddi Trial included 8725 patients having all types of non-cardiac surgery over the past four years from 55 hospitals across Australia, New Zealand, Hong Kong and South Africa. Hospitals in WA included RPH, Fiona Stanley, Sir Charles Gairdner and Rockingham. Half of the patients received a single 8 mg dose of dexamethasone and the other half received placebo during their surgery and were followed up for six months after surgery.

The findings showed that 8.1 per cent of patients who received dexamethasone experienced a wound infection at 30 days after surgery, compared to 9.1 per cent in the placebo group, indicating no evidence of any major differences between the groups.

“We have clearly shown that administering dexamethasone during surgery does not increase the risk of wound infection, in particular in patients with diabetes. Hence, it is safe to use this drug when clinically indicated.” Professor Corcoran said.

“After a surgical procedure, there is always a concern that patients will suffer a major complication. There is an ongoing need to run large scale clinical studies such as PADDI, which produce reliable results to determine how to reduce major complications after surgery and to improve the safety of our patients.”

This trial was funded by the National Health and Medical Research Council (NHMRC) and Monash University. The trial was awarded the largest valued NHMRC project grant in the 2015 project grant round.

Watch the PADDI trial results webinar (external link).

Previous Next
Last Updated: 18/01/2024
  • Facebook
  • LinkedIn
  • YouTube

Acknowledgement of Country

East Metropolitan Health Service respects and acknowledges the Whadjuk people as the traditional custodians of the land on which we work, and of elders past and present.

Footer menu

  • wa.gov.au
  • Copyright
  • Disclaimer
  • Privacy
  • Sitemap
  • Contact Us

Brought to you by the Department of Health, Western Australia

© Government of Western Australia 2018 to